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Objective: Despite the using of some biological and clinical criteria for the definition of polycystic ovarian syndrome (PCOS) such as hyperandrogenism 
and menstrual dysfunction. However, the complex mechanism of this syndrome is still of interest to researchers, and began to investigate new 
parameters intervene in the pathogenesis of this disease including leptin and C-reactive protein (CRP). However, the role of these parameters is still 
not clear and under controversy. This study aimed to investigate the relationship between serum leptin levels with CRP in patients diagnosed with 
PCOS attending Aleppo Gynecology University Hospital.
Methods: The study included 46 patients and 25 healthy control subjects with the same range of age- and body mass index. Related 
parameters were measured for both groups: Serum glucose, leptin, insulin and CRP levels, and homeostasis model assessment of insulin resistance 
(HOMA-IR).
Results: Serum leptin levels were significantly correlated with CRP only in PCOS group (p<0.05). The levels of CRP and leptin were significantly higher 
in the PCOS group in comparison with the control group (p<0.05). There were a correlation between leptin with CRP only in patients with IR group 
(p<0.05), and there was a correlation between CRP and HOMA-IR only in PCOS group (p<0.001), but not in the control group.
Conclusion: Increased leptin, CRP levels in PCOS patients is independently associated with IR and make these parameters more important to take 
them in consideration.
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INTRODUCTION
The polycystic ovary syndrome (PCOS), which is characterized by 
hyperandrogenism, chronic anovulation and infertility, is one of the 
most frequent endocrine disorders in women. In addition to the 
reproductive abnormalities, a significant proportion of PCOS women 
suffers from obesity, insulin resistance (IR) and features of the 
metabolic syndrome [1,2].
IR, as a major abnormality associated with PCOS, represents a disorder 
with increased risk of type 2 diabetes [3] and is usually associated with 
an increase in inflammatory markers [4].
IR is now known to be intrinsic to PCOS, present in approximately 
50–70% of PCOS women independently of obesity, and contributing in 
a major way to its pathogenesis [5]. IR and hyperinsulinemia promote 
abnormal ovarian androgen secretion and subsequently abnormal 
follicular development leading to dysfunctional ovarian and menstrual 
activity [6].
The cause of IR in PCOS appears to be a post binding defect in insulin 
receptor-mediated signal transduction [7]. IR is believed to be associated 
with chronic inflammatory response, which is characterized, by 
abnormal cytokine production and the activations of pro-inflammatory 
signaling pathways [8].
In recent years, several studies have demonstrated a high risk 
for impaired glucose tolerance and type 2 diabetes mellitus in 
PCOS [9]. It has not yet been clarified whether this increase in risk 
is related to endocrine abnormalities associated with PCOS, such as 
hyperandrogenemia, or it is a consequence of the anthropometric or 
metabolic abnormalities frequently observed in PCOS women.
The adipose tissue-derived hormone leptin is produced in proportion 
to fat stores. Circulating leptin serves to communicate the state of body 
energy repletion to the central nervous system in order to suppress 
food intake and permit energy expenditure. Adequate leptin levels 
permit energy expenditure in the processes of reproduction and growth 
and similarly regulate the autonomic nervous system, other elements 
of the endocrine system and the immune system [10]. Conversely, a 
lack of leptin signaling due to mutation of leptin (e.g., ob/ob mice) or 
the leptin receptor (e.g., db/db mice) in rodents and humans results 
in increased food intake in combination with a reduced energy 
expenditure phenotype reminiscent of the neuroendocrine starvation 
response (including hypothyroidism, decreased growth, infertility, and 
decreased immune function) in spite of their obesity [11].
Caro et al. reported that leptin and insulin receptors deficient mice 
showed elevated testosterone, infertility and IR, which are reminiscent 
of PCOS in humans [12]. The role of leptin in PCOS is under investigation 
since the disease involves impairment of reproduction and nutrition [13].
Markers of chronic subclinical inflammation such as C-reactive protein 
(CRP) or interleukin-6 (IL-6) have been shown to be independent 
predictors of risk for the development of type 2 diabetes [14-16]. 
Consistently increased CRP levels have been reported in PCOS 
patients [17], supporting the hypothesis that PCOS increases diabetes 
risk by activating chronic inflammation. Circulating CRP and IL-6 
concentrations are correlated to obesity as well as to IR [18-20].
Sampson and coworkers showed that increased levels of CRP are 
associated with increased cardiovascular risk in PCOS [21]. Elevated 
CRP in association with hyperinsulinemia is a significant risk factor for 
cardiovascular diseases and that plays a key role in the development of 
the PCOS [22].
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                 ABSTRACT
Some studies have investigated the association between CRP with IR 
and PCOS. They have shown a positive correlation between the increase 
in CRP with IR and PCOS [4,23]. In another study, plasma leptin levels 
were found to correlate closely with inflammatory cytokine levels 
tumor necrosis factor-alpha (TNF-α, IL-6) and with acute phase 
proteins (CRP, alpha-1-antitrypsin) [24]. It is still not known whether 
these parameters of chronic inflammation are primary or secondary to 
obesity and/or IR especially since short-term administration of IL-6 in 
humans failed to impair insulin sensitivity [25].
The present study aimed to evaluate CRP serum level changes in PCOS 
comparison with healthy controls matched in age and body mass index 
(BMI), and to determine in one hand the association between leptin 
and CRP in PCOS patient, and in other hand determine the correlation 
between leptin, CRP and IR (according to the homeostasis model 
assessment [HOMA] in patients with PCOS).
METHODS
This was a cohort study involving 46 PCOS patients who Attended 
Aleppo Gynecology University Hospital and 25 age and BMI matched 
healthy controls were recruited.
Patient’s characteristics
The patient inclusion criteria included females aged 18–35 years, Arab 
population, BMI> 25 kg/m2. The criteria for diagnosis of PCOS are the 
2003 Rotterdam ESHRE/ASRM criteria: (1) Oligo and/or anovulation; 
(2) clinical and/or biochemical signs of hyperandrogenism (patients 
presented with hirsute, acne or alopecia, and/or increased circulating 
levels of testosterone; (3) polycystic ovaries (ovarian morphology 
was assessed using transvaginal ultrasound), and exclusion of other 
etiologies [26]. 25 healthy, fertile nonpregnant females with cross-
matched age were recruited as a control group.
In all participants, BMI, HOMA-IR, serum levels of fasting glucose, 
insulin, leptin, CRP were assessed. BMI was calculated as weight in 
kilograms divided by height in meters squared for all eligible subjects.
The exclusion criteria were: Patients who received gonadotropins, 
hormonal contraception, metformin, or thiazolidinediones in the 
3 months before the study, the patients with hyperprolactinemia 
(morning plasma prolactin ≥30 ng/ml) or other endocrine, hepatic, or 
renal disorders.
Laboratory assays
Venous blood samples (10 ml) collected between 8 and 10 a.m. after 
overnight fasting and were allowed to clot and centrifuged at 3000 rpm 
for 5 minutes. Serum was stored at −20°C for biochemical assays. 
Blood samples were taken from patients and controls on days 2-5 of 
their menstrual cycles (early follicular phase), but blood samples were 
taken randomly for those suffering from severe oligo or amenorrhea. 
Hormonal and biochemical assays were performed at the researches 
Laboratory of the Faculty of pharmacy, Aleppo University. Glucose 
level was measured by glucose oxidase/peroxidase method and 
spectrophotometric quantitation (Biosystems SA, Spain).
Insulin was detected by enzyme-linked immunosorbent assay 
(Sandwich-ELISA) kits (DiaMetra Catalog No: DCM076-7, ITALY), its 
analytical sensitivity was 0.25 μU/ml. IR was assessed using the HOMA-
IR by the following formula: HOMA-IR (mg/dl × μU/ml) = fasting blood 
glucose (mg/dL) × fasting insulin (μU/ml)/405. The patients were 
considered as insulin resistant if HOMA-IR >3.875 [27,28]. Leptin 
was detected by Sandwich-ELISA kits (Diagnostic Automation, INC 
Catalog No: 1742-6, USA), its analytical sensitivity was 0.3 ng/ml. CRP 
was measured by immune-turbidimetric methods with commercially 
available Latex kits (Biosystems SA, Spain).
Statistical analyses
Data were analyzed using Statistical Package for the Social Science, 
version 20 (SPSS, Chicago, IL, USA) and were expressed as a mean ± 
standard deviation. Comparison between patients and controls was 
performed with independent samples “t-test,” one-way ANOVA, and the 
Tukey post hoc test. The degree of correlation between leptin and the 
variables of interest was assessed using Pearson’s correlation coefficient.
In addition, multivariate stepwise regression analysis was performed 
to identify important predictors of leptin. For all tests, a probability 
(*p<0.05) was considered statistically significant.
RESULTS
The measured parameters of PCOS and control groups: Age, BMI, 
hormonal, and biochemical levels are shown in Table 1. All parameters 
were comparable between the two groups, considering p<0.5 if the 
differences are significant.
PCOS patients and healthy controls had no significant differences in age, 
BMI (p>0.05). Fasting leptin, CRP as well as HOMA-IR, were significantly 
higher in PCOS patients than in healthy controls (p<0.05) as shown in 
Table 1.
To study the correlation between leptin levels with CRP levels, without 
dividing the study groups into IR or non-IR (NIR), we applied Pearson 
correlation test; in which r values ranging from −1 to 1 and probability 
(p<0.05) was considered statistically significant as shown in Table 2.
Table 3 showed that there were significant differences between the four 
groups in CRP and leptin serum levels (p<0.05). These results were 
Table 1: Age, anthropometric and biochemical parameters 
investigated in polycystic ovary syndrome patients and in age, 
body mass index matched healthy control subjects





Age (years) 24.13±5.48 25.6±5.41 NS
BMI (kg/m2) 28.05±3.87 29.82±3.07 NS
HOMA-IR (mg/dl μIU/ml) 5.64±2.16 3.82±1.52 0.000*
Fasting leptin (ng/ml) 19.52±7.45 10.7±2.48 0.000*
CRP (mg/l) 12.69±5.51 5.97±2.36 0.000*
*Indicates existence of statistically significant p<0.05 value. NS: Nonsignificant, 
BMI: Body mass index, CRP: C-reactive protein, PCOS: Polycystic ovary 
syndrome, HOMA-IR: Homeostasis model assessment of insulin resistance
Table 2: Baseline Pearson correlations coefficients (R) of leptin 
with C-reactive protein in polycystic ovary syndrome and 
control groups
Variables Leptin in PCOS (n=46) Leptin in control (n=25)
R p R p
CRP (mg/l) 0.605 0.000* 0.158 0.448
*Indicates existence of statistically significant P<0.05 value. CRP: C-reactive 
protein, PCOS: Polycystic ovary syndrome
Table 3: Mean differences of leptin and C-reactive protein 
between the four groups (patient-insulin resistance, 
patient-noninsulin resistance, control-insulin resistance, and 
control-noninsulin resistance)
Variables PCOS-IR PCOS-NIR Control-IR Control-NIR p
CRP (mg/L) 14.8±5.1 8.4±3.5 7.5±2.1 5.1±2.1 0.000*
Leptin
(ng/ml)
22.3±7.2 13.8±3.7 12.7±2.2 9.6±2 0.000*
*Indicates existence of statistically significant p<0.05 value. PCOS-IR: Polycystic 
ovary syndrome insulin resistance, PCOS-NIR: Polycystic ovary syndrome 
noninsulin resistance, IR: Insulin resistance, NIR: Noninsulin resistance, 
CRP:  C-reactive protein
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explained by using Tukey post hoc test, in this, we noticed that the mean 
serum levels of CRP were significantly higher in patient-IR (14.8 ± 50.1) 
than in patient-NIR, control-IR and control-NIR, respectively (8.4 ± 3.5, 
7.5 ± 2.1, 5.1 ± 2.1), and the mean serum levels of leptin were significantly 
higher in patient-IR (22.3 ± 7.2) than in patient-NIR, control-IR and 
control-NIR respectively (13.8 ± 3.7, 12.7 ± 2.2, 9.6 ± 2).
We noticed that there was a correlation between leptin with CRP 
in PCOS-IR (p<0.05), but no correlation between them in PCOS-NIR 
(p=0.301) as shown in Table 4. There was a correlation between CRP 
and HOMA-IR only in PCOS group (p<0.001) and no correlation between 
them in the control group (p=0.094) as shown in Tables 4 and 5.
Multivariate stepwise regression analysis was performed for PCOS 
patients to identify the best predictor factors of leptin levels. Leptin was 
introduced as a dependent variable and BMI, fasting insulin, CRP and 
HOMA-IR (variables that have been significantly correlated with leptin, 
(data not shown) [29], were introduced as independent variables. 
After adjusting the effects of other variables, only CRP was found to be 
independent predictor of leptin levels (β = 9.137, p=0.000) and showed 
that CRP levels determined 36.6% serum leptin concentration, while 
other variables were below of this percentage. Thus, the proposed 
model was: Leptin level = 9.137 + 0.818* CRP. This equation was 
considered because it had the best-adjusted r2 = 0.366. Therefore, 
serum leptin levels appear to be determined by serum levels of CRP, 
which seemed to be the most important influencing factor.
DISCUSSION
The increasing mean values of leptin in the PCOS group are in agreement 
with several studies which attributed this to the presence of the case of 
resistance to leptin in PCOS patients [24,30].
Taking in consideration the IR, we noticed in Table 3, that leptin was 
higher in Patient-IR than Patient-NIR, which is in agreement with many 
studies [31,32], and lead to suggest a relationship between leptin and 
insulin receptors in the pathogenesis of PCOS [29].
The increasing level of CRP in the PCOS group is correlated to CRP 
meta-analysis, which showed that circulating CRP was 96% higher in 
women with PCOS compared to controls. The present meta-analysis 
of the mean differences in CRP, IL-6 and TNF-α clearly indicates that 
CRP is a circulating marker of the pro-inflammatory state in PCOS as 
evidenced by the 2-fold elevation in circulating CRP in women with 
disorder compared to controls. There is no difference in the levels of 
IL-6 or TNF-α between both groups [33].
We noticed in Table 2, there was a correlation between serum leptin 
levels and CRP only in PCOS group, and this could be explained that 
PCOS has also been described as a low-grade inflammation state 
characterized by elevated levels of CRP [34]. One of the reasons that 
makes serum leptin levels high in PCOS is the CRP, which in turn 
binds with leptin and impairs leptin transport across the blood-
brain-barrier and leptin signaling at a cellular level and this is one 
of the proposed mechanisms that lead to a defect in the function of 
leptin. Many studies have shown an association between the CRP 
with leptin, wherein a survey study of the extent of leptin association 
with a number of serological proteins, showed that the greatest 
affinity was with the CRP, and these studies also showed that CRP, 
which binding to leptin, prevented it entering the blood-brain-
barrier and thus inhibition of its physiological signaling to cause a 
feeling of satiety [30].
In addition, we noticed that CRP was higher in PCOS-IR group than PCOS-
NIR, Moreover, Table 4 showed a correlation between leptin with CRP in 
PCOS-IR, and Table 5 showed a correlation between CRP and HOMA-IR 
only in PCOS group. These findings are consistent with several studies 
have shown a positive relationship between the increasing CRP with IR 
and PCOS [4,23,35], so we can suggest that the CRP levels are higher 
when there is IR in comparing with the absence of resistance. However, 
our results conflicted with other studies, which showed that there were 
no differences in serum CRP levels between both groups [36], and there 
was no correlation between CRP and HOMA-IR [37].
To explain the correlation between CRP, leptin and IR, we take in 
consideration that adipose tissue-derived cytokine expression (tumor 
necrosis factor-α, leptin and IL-6) may be an important contributor 
to low-grade chronic inflammation. In other words, the accumulation 
of visceral adipose tissue may be a key factor underpinning features 
of the metabolic syndrome and of low-grade chronic inflammation. 
These combined observations would also explain the correlation 
of insulin sensitivity to CRP [19]. It appears that adipose tissue in 
general; visceral adipose tissue in particular, plays a key role in 
regulating inflammation. Notably, CRP is primary synthesized in the 
liver and regulated by the pro-inflammatory cytokine IL-6 and TNF-α 
in adiposities [38].
The previous studies suggest that the cytokines, arising partly from 
adipose tissue, could possibly be responsible for the metabolic 
abnormalities associated with IR. In this respect, many markers 
are proven associated with IR, metabolic syndrome, and diabetes 
among which CRP has been the most studied marker. However, the 
causal association has not been proven yet. One hypothesis is that 
the inflammatory cytokines that stimulate the hepatic production 
of acute phase proteins are mainly secreted by the adipose tissue 
excessively and that such cytokines may result in IR by indirectly 
causing the phosphorylation and proteosomal degradation of insulin 
receptor substrates or by indirectly interfering with the insulin 
receptor substrate interaction [4]. The decrease of serum CRP 
levels during metformin therapy is in accordance with the known 
beneficial metabolic effects of this drug and suggests that CRP or 
other inflammation parameters could be used as markers of treatment 
efficiency in women with PCOS [39].
There were many clinical argumentative studies about the role of leptin 
and CRP in PCOS patients with IR, so this study comes to clarify the role 
of them in PCOS pathogenesis by assessment the serum levels of leptin 
and CRP in Syrian PCOS patients and healthy groups, in addition to 
the others classical related parameters. Therefore, the more attention 
should be paid to leptin and CRP in the treatment of PCOS, and more 
clinical studies should be done to make sure about our model to 
calculate leptin levels. Perhaps further studies with larger sample sizes 
and long-term follow-up will help to support our results.
Table 4. Baseline Pearson correlations coefficients (R) of leptin 
with C-reactive protein in polycystic ovary syndrome group 
after dividing them into patient insulin resistance and patient 
noninsulin resistance
Variables Leptin in patient-IR 
(n=31)
Leptin in patient NIR 
(n=15)
R p R p
CRP (mg/l) 0.464 0.008* 0.285 0.301
*Indicates existence of statistically significant p<0.05 value. IR:  Insulin 
resistance, NIR: Noninsulin resistance, CRP:  C-reactive protein
Table 5: Baseline Pearson correlations coefficients (R) of 
C-reactive protein with homeostasis model assessment of 
insulin resistance in polycystic ovary syndrome and control
Variables CRP in PCOS (n=46) CRP in control (n=25)
R p R p
HOMA-IR 0.475 0.001* 0.342 0.094
*Indicates existence of statistically significant p<0.05 value. 
HOMA-IR:  Homeostasis model assessment of insulin resistance, CRP: C-reactive 
protein, PCOS: Polycystic ovary syndrome
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CONCLUSION
Serum leptin, CRP and HOMA-IR were higher in PCOS group than 
matched healthy control. Serum leptin levels were significantly 
correlated with CRP only in PCOS group (p<0.05). Increasing serum CRP 
levels in PCOS-IR group more than PCOS-NIR, suggests the involvement 
of inflammatory processes in PCOS, and the correlation between CRP 
and IR, which are the main factors in PCOS women.
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